News Priveterra Acquisition Corp. II

Equities

PMGM

US8765451047

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-16 pm EDT			5-day change	1st Jan Change
11.21 ^USD	+1.72%		-.--%	+2.00%

2023	Priveterra Acquisition Corp. II Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Priveterra Acquisition Corp. II Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AEON Biopharma Announces Redemption of Public Warrants - March 29, 2024	Apr. 01	AQ
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants	Mar. 30	AQ
AEON Biopharma Announces Redemption of Public Warrants	Mar. 29	AQ
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results	Mar. 29	AQ
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine	Mar. 19	AQ
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements	Mar. 19	AQ
AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference	Jan. 18	AQ
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine	Dec. 12	AQ
Priveterra Acquisition Corp. II Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
AEON Biopharma Reports Third Quarter 2023 Financial Results	Nov. 13	AQ
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine	23-10-19	AQ
AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®	23-08-29	AQ
AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache	23-08-24	AQ
Priveterra Acquisition Corp. II Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
Tastemaker Acquisition Corp. has Changed its Name to Priveterra Acquisition Corp. II	23-07-17	CI
Tastemaker Acquisition Corp. Announces the Resignation of Christopher Bradley as Chief Financial Officer	23-07-05	CI
Tastemaker Acquisition Corp. Announces Board Changes	23-07-05	CI
Tastemaker Acquisition Corp. Announces CEO Changes	23-07-05	CI
Tastemaker SPAC calls off nearly $1 bln planned merger with Quality Gold	23-06-22	RE
Tastemaker Acquisition : Announces Termination of Business Combination Agreement - Form 8-K	23-06-22	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Priveterra Acquisition Corp. II

Equities

PMGM

US8765451047

Summary

Filters